Side-by-side comparison of AI visibility scores, market position, and capabilities
Wilmington DE YC W23 AI clinical notes EHR for mental health therapists; $728K total ($500K YC seed Oct 2023) with HIPAA-compliant AI notes and EHR integration competing with SimplePractice for independent therapist documentation.
Orchid is a Wilmington, Delaware-based AI-powered EHR platform for mental health professionals — backed by Y Combinator (W23) with $728,000 in total funding including a $500,000 seed in October 2023 from Y Combinator — providing independent mental health clinicians (therapists, psychologists, counselors) with HIPAA-compliant AI clinical notes that integrate with any existing EHR, automating note-taking to free time for patient care. Launched Orchid AI in July 2024, with e-prescribing planned for 2025, Orchid streamlines the administrative workflows and clinical documentation burden that forces mental health professionals to spend 2-3 hours daily on paperwork that competes with patient care time. Founded in 2020, targeting the solo and small group independent mental health practice market.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.